to annual data for nine EU countries, for the period 1984-95; we find strong impacts of incentives, public policies, and institutions on private aggregate agricultural R&D investment; we find interactions between public policies and institutions. Furthermore, for the EU countries in this study, the evidence is that public agricultural R&D crowds-out private agricultural R&D investments at low levels of private R&D, but at high levels of private R&D, they are complementary.
Private Agricultural R&D First, we review the economics of private R&D investment decisions and selective empirical results, and second, we summarize the nature of private agricultural R&D investments in Western Europe.
General Issues
Private firms and individuals conduct research because they expect pecuniary rewards or payoffs. A number of conditions affect these decisions, and at the industry level, R&D expenditures are the results of aggregation over individual firm decisions. A useful discovery or innovation may enable reductions in the cost of producing an existing good, improve the quality of an existing good, or enable the development of a new good. The cost of discoveries is affected by the price of research inputs, the efficiency of the organization of research, the technological opportunities, the stock of available knowledge that can be drawn on, and the tax treatment of R&D expenditures. 3 The returns to private R&D are determined by the potential size of the market for the discovery or aggregate demand, the ability of the discoverer to appropriate benefits, and the expected length of the useful economic life of a discovery. The size of the market for the discovery is affected by the market structure for existing products. For example, monopoly in the original product market reduces the demand for a discovery over competition in that market. 4 Each national market for goods and services is affected by regulatory policies and the existence of close substitutes. The openness of a country to trade is a major factor affecting the total size of the market for a discovery.
The ability of a discoverer to appropriate benefits from a discovery depends critically on the nature of the discovery, institutional mechanisms that exist for protecting intellectual property, and the general efficiency of public institutions. Once made, a discovery is either a pure public good or an impure public good. It is a pure public good when benefits are nonrival, that is, one user of the discovery does not affect the quantity or quality of knowledge available to other potential users, and nonexcludable, that is, the benefits from using the discovery cannot feasibly be excluded from those who want to use it, even though they pay nothing to the discoverer. 5 Furthermore, the usevalue of the discovery is private information to the user, and he or she has no incentive to accurately reveal it. With these conditions, a discoverer cannot expect to appropriate (significant) benefits from other private users by charging fees for use.
A private discoverer, however, can use a pure public good discovery to produce and sell a product or to support an ongoing business, for example, to manufacture and market a durable good or to produce and market hybrid seeds. By attempting to keep the discovery secret and having a head start moving down the learning curve, a firm may be able to obtain some benefits from pure public good discoveries. 6 However, if the discovery is ever revealed publicly or can be reverse engineered, the pure public-good attributes of the discovery will come to play, and the discoverer will share benefits of the discovery with all other users. 7 These are reasons why private firms find research programs focused on discoveries that are of a pure public-good nature to be generally poor private investments, why large firms tend to view this research more favorably than small ones, and why private provision of these discoveries, although positive, is much less than the social optimum.
Economies of size enable large firms to respond to the high-income consumer by providing a stream of new products through the use of both science and communication.
8 R. W. Ward, who emphasizes the joint importance of "new products" and "images," contends that attracting the most technically and possibly the most artistically competent employees is relevant in very large food firms.
9 J. C. M. Van Trijp and J. E. B. M. Steenkamp observe that the R&D and marketing functions are linked in consumer-oriented new product design. 10 Moreover, the production of commercially successful items seems to require a broad multidimensional innovation approach. So, global size relates primarily to firm incentives.
When discoveries are impure public goods in the sense that they are excludable, the potential for discoverers to capture benefits from their discoveries increases. The legal institution of intellectual property rights (IPRs)-for example, patents, breeders' rights, copyrights, trade secrets, trademarksis the main mechanism for accomplishing this. These property rights are created by nation-states and enforced by nation-states and international conventions or treaties. With patents, breeders' rights, and copyrights, the discoverer is given an exclusive right to control the use, including charging a fee for use, for a finite time period. This institution provides an added method by which discoverers can expect to obtain remuneration from others for the use of their discoveries.
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Western European countries harmonized their patent laws in 1977 and adopted a "first-to-file-for-a-patent" rule in deciding priority claims to patentable inventions. With this rule, patents are issued to the first person to file an application that can validly claim to have made an invention, and the patents last for 20 years from the date of application.
12 The first-to-file rule seems to provide less protection to discoverers than the first-to-invent rule applied by the U.S. Patent and Trademarks Office. Given a fixed length of term for a patent, the first-to-invent rule provides an incentive for firms who use discoveries to support a competitive edge in a product market to delay patent application until another firm has applied for a patent because the inventor can later prove that he or she was the first to discover. The first-to-file rule seems likely to lower transaction costs associated with litigation over who is the "first" relative to a first-to-invent rule. 13 Until the 1980s, intellectual property protection of biological materials had been limited primarily to secrecy. This changed first with the introduction of breeder rights, for example, plant variety protection certificates, in the 1970s, and then the extension of patents to biological materials (living organisms, plants, and nonhuman mammals) in the 1980s. The applications of recombinant DNA techniques have resulted in transgenic plants and animals being created, and the courts have ruled that these innovations have been large enough that they are not the products of nature and hence can be patented. The expected returns to private biotech research have been clouded, however, by environmental and health issues raised by antibiotech interest groups. 14 If no institutional structure exists to easily enforce them, the granting of intellectual property rights to discoveries is of little value. For example, if the court system is very slow, legal fees are high, and court decisions are frequently reversed, an insecure institutional structure will reduce the expected private benefits of discovery relative to their full potential value. Failure to compensate for positive spillovers might be a negative incentive for private R&D investments. Hence, an effective legal system reduces uncompensated spillovers, which must occur for private incentives to direct efforts to private R&D.
Generally, insecure contractual and property rights discourage private investments by reducing the expected return and increasing the riskiness of investment. 15 Insecure private property rights frequently arise from weak and inefficient institutions, as reflected in bureaucratic delays in the provision of civil services, weak contract enforcement, and public takings of private property without fair compensation. 16 In the United States, R. Levin et al. surveyed firms operating in 130 narrowly defined lines of business and found that patents were regarded as a highly effective means of appropriating returns primarily in drugs, organic chemicals, and pesticides. 17 Outside the pharmaceutical and chemical industries, firms reported that the advantages of having a head start and the "ability to move quickly down the learning curve" were more effective means of appropriating than patents. Biotechnology, however, was not covered in that survey. For process innovations, firms in most industries viewed secrecy as more effective than patents. 18 Thus, aggregate expenditures for an industry are determined by complex interactions among participants. 19 The transfer (degree of publicness), the appropriability (IPRs and spillovers), and cooperation among affected firms (or noncooperative) affect aggregate investment. 20 Although highly structured theoretical models provide clear predictions, the empirical evidence has been quite mixed, and some of it is quite weak. For example, W. Cohen and R. Levin concluded that too much emphasis has been placed on the effects of industrial structure on private R&D investments and not enough on other issues. 21 Spillover or borrowing effects reflect some of the new R&D research at the industry level. In relatively early work, J. Bernstein and M. I. Nadiri found significant production-cost-reducing and factor-intensity effects of a company's own R&D and interindustry R&D spill-ins. 22 J. D. Adams found that within-and between-industry R&D spill-ins operated with a long lag but were a significant factor in explaining industrial productivity. 23 R. E. Evenson and Y. Kislev, and also Evenson and D. Gollin, have shown transnational transfers of plant genetic material and crop varieties to be important to general varietal improvement, but borrowing is costly-knowledge does not spill-in costlessly. 24 
Agriculture in Europe
In the EU and Organization for Economic Cooperation and Development (OECD) countries, a large share of private agricultural R&D is invested in agricultural inputs-agricultural chemicals, plant breeding, farm machinery, and animal health-and food and kindred products but relatively little (less than 10%) in farm-level technologies. 25 In the EU, private agricultural R&D has been focused on agro-chemistry (folliculars, fertilizers, micronutrients, fungicides, insecticides, and soil disinfectants), plant breeding and varietal development, plant nutrition, plant growth regulators, plant parasitology, marine aquaculture, raw material production from cultured media (e.g., corn syrups, sugars), enzymatic conversion of starch to sugars, biotechnology in plants, combine and harvesting machine development, safety and ergonomics in farm machinery, and veterinary pharmaceuticals.
The focus of private agricultural R&D differs across Western European countries. In the United Kingdom, agricultural chemicals, machinery, and feeding stuffs have been important. 26 The Cambridge Plant Breeding Institute was transferred from the public sector to the private sector (Unilever) in 1987. Unilever then sold it to Monsanto in 1998. In the Netherlands, private research on horticultural crops is large. In France, private R&D-for example, in Vilmoria, the Cooperative Society for Research and Experimentation of the Eastern Pyrenees, the Technical Institute of the Sugar Beet Industry and the co-op Limagrain-is primarily focused on plant breeding, pesticides, and fertilizers. In Germany, private R&D is focused on pesticides and fertilizers, for example, companies like BASF, BAYER, , and Hoechst; agriculKali ϩ Salz tural machinery, for example, Deutz and Mercedes; and animal feed and pharmaceuticals. In Sweden and Denmark, private research is on fertilizers, forestry, and communication systems.
Patent laws for the EU countries have been strengthened over the past 4 decades and are in general much stronger than in developing countries, but somewhat less than in the United States.
27 Among EU countries, Finland, Portugal, and Ireland have had relatively weak patent rights over the period 1960-90, and Sweden, Germany, and Denmark have significantly strengthened their patent rights over time (see table 1 ).
Cross-country comparisons of private and public agricultural R&D expenditures are made difficult by the fact that each country has its own definition of what is included in private and public research, and the restructuring of public agricultural research in some of these countries over the past 2 decades has changed what is now included in public and private research. 28 For example, in the United Kingdom, some public agricultural research institutions have been sold to the private sector, 29 and in the Netherlands, research institutions of the Ministry of Agriculture, Nature Management, and Fisheries have been turned into a quasi-public institution (DLO). German data have special problems because of the fact that two separate countries existed before 1990, and pre-1990 data cover only West Germany.
Even with these deficiencies, it is useful to present some comparisons across EU countries. Table 2 presents information showing large differences in the share of private agricultural research expenditures in total public and private agricultural research expenditures of 14 EU countries for 1985, 1990, and 1995. The United Kingdom, Netherlands, and Sweden stand out for their large private sector shares, and Germany, Ireland, and Spain have unusually small shares. Furthermore, these data do not suggest a strong increase in the private R&D share over 1985-95. However, it is safe to conclude that private agricultural R&D has more of an input focus than public agricultural R&D.
The Econometric Model, Data, and Results
An econometric model of national aggregate annual private R&D investment is specified and fitted to panel data for nine EU countries (Austria, France, Germany, Italy, Netherlands, Portugal, Spain, Sweden, and United Kingdom) over 1986-95. These countries account for a very large share of agricultural product in the EU: about 85.6%. Unavailability of private R&D expenditure time series data has been the main restriction to including more countries in the data set. Although the countries included in the panel collect and report R&D in line with the Frascati Manual, some specifications differ from the OECD standard. If definitions for the data are not identical, this makes meaningful comparisons more difficult, and it can be a source of measurement errors. Problems are most likely to arise with the definitions of the science and technology indicators and with methodological changes during the sample period (see appendix).
The Econometric Model
Definitions of variables as well as sample mean values, minimum and maximum values, and the standard deviations are presented in table 3. 30 Figure 1 displays the pattern of growth of (real) private agricultural R&D investments in each of the nine sample countries over 1984-95. These investments comprise the dependent variable to be explained by our econometric model.
The econometric model of aggregate gross real private R&D investment or expenditure is one that incorporates variables representing the effect of incentives, public policies, institutions, and a time trend. The incentives relate primarily to the size and composition of agricultural output. Each country has a set of institutions represented by country-specific indicators of patent rights, efficient bureaucracy, civil contract enforcement, and economic openness, which are hypothesized to affect the rate of private investment. Public policies such as public agricultural research investment decisions are expected to affect private R&D investment decisions. Transnational R&D capital is also expected to affect domestic private R&D investments.
The exact econometric specification of the private aggregate agricultural R&D investment equation is ln (PrivateR&DInv ) p where is a random disturbance term representing the effects of omitted m lt variables that are peculiar to both a country (l) and time period (t). It has a zero mean and constant variance over time for any given country, but it differs across countries, and the disturbances are assumed to be contemporaneous correlated across countries. We assume that any unmeasured time-invariant country effects are uncorrelated with the time-varying regressors. 31 Homogeneity of degree zero is imposed on the R&D investment equation by deflating all nominal flow magnitudes by the GDP price deflator index. 32 We now present and discuss hypotheses. We expect a higher private real interest rate or the opportunity cost of private investment funds to reduce the net present value of private R&D investments, other things equal, and to reduce the demand for private R&D investment, that is, . Private R&D b ! 0 2 capital represents a stock of past discoveries that may be useful in future discoveries because they provide key building blocks to future discoveries, but the exhaustion of the innovative potential might be occurring faster than it is being restored, that is, "using up" some of the innovative potential. 33 Hence, the expected sign of is a priori uncertain. Private and public R&D b 3 capital seem likely to interact in affecting private agricultural R&D investment decisions, and they might be complements or substitutes:
If private research and public research capital are complements, then will b 13 be positive, and if they are substitutes or if "crowding-out" of private by public investment occurs, then will be negative. Thus, the expected net b 13 effect of the private R&D stock on current private R&D investment is a priori uncertain.
Private agricultural R&D investments in one country may affect investment decisions in other countries through transnational R&D transfers. These transfers are really of two types: (i) the size of the pool of generally accessible knowledge that is available from the outside for use by a particular country's scientists and (ii) the size of the borrowable stock of R&D from the outside, that is, knowledge relevant to the country's agriculture, or where the "technical distance is short." 34 For private R&D, transnational privately funded R&D is "closer" to the private R&D of a country than public R&D and should be a substitute. Second, transfers proxy the product market rivalry between firms in different countries. 35 Evenson, and also D. K. N. Johnson and Evenson, present evidence of spill-ins for patented innovations across selected European countries. 36 These transfers are expected to be larger and more direct when the R&D is undertaken by large multinational companies, but even for R&D undertaken by domestic companies, some transnational externalities may occur. If transfer discoveries can be used directly, we expect , or that transnational private R&D b ! 0 4 capital crowds-out private R&D investment. Alternatively, if domestic research must be undertaken to adapt new spill-in technology to local conditions, for example, costly borrowing, then we expect .
In our model, we adopt a 2-year lag for the international transmission of agricultural knowledge. The main reason is the likely slower transmission of information and technology when it must cross national boundaries, for example, because of different languages, cultures, and so on. In our model, the regional stock of knowledge from borrowing is obtained by weighing R&D expenditures with the share of a country's output from wheat and milk production, which is a proxy for similarity of agricultural product mix. 37 The regional borrowable knowledge stock is formed by the general stock of borrowable knowledge less a country's own contribution. 38 The marginal effect of public R&D capital on private agricultural R&D investment is:
If public R&D is generally crowding-out private R&D, then the sign for equation (3) will be negative. We expect the main effect of public R&D capital in agriculture to be a substitute for private R&D, but if the interaction term with private R&D capital is positive, that is, , then at some level of b 1 0 13 private R&D capital, public R&D capital complements private R&D investment. A country having done more private R&D in the past then allows it to make better use of the public R&D capital.
The potential size of the national market for private agricultural innovations is proxied by the volume of agricultural production (AgOutput) and the crop share of final agricultural production (CropShare), both lagged 1 year. We expect the payoff to private agricultural R&D to be positively related to the size of local agriculture, or , to be positive. Livestock-related sectors b 6 such as milk, swine, beef, and poultry are important to EU agriculture, as they account for 45% of agricultural output. The livestock sector, which has been highly protected from external competition, has been the focus of new technology development, for example, automation, artificial insemination, and new feeding systems for the local environment. Crop production has been heavily focused on supporting the livestock industry and on wine production. Hence, the expected sign of is negative. b 7 Next, consider the effects of variables representing the effects of institutions. Stronger patent rights are expected to increase private R&D investments because private firms can expect to obtain a larger share of the social benefits from innovations resulting from their research and development, that is, , but with a patent life of 20 years, we do not expect to preclude b 1 0 9 future related inventions that must build on past inventions. The speed and efficiency of civil services is expected to facilitate domestic private R&D investment. If obtaining needed permits and licenses involves slow and cumbersome processes, this will weight heavily against domestic private R&D investment decisions. Furthermore, if efficient bureaucratic and contract enforcement are complementary, we expect to be positive: Although the EU is a developed region, the extent of development and property rights differs. If the innovations needed by farmers must be highly tailored to local geoclimatic conditions, then strong rights for local compared with foreign firms would be important to private R&D investments, that is, this could lead to local protectionism and being negative.
The country dummy variables in equation (1) are country-specific [D(l)] intercept terms or fixed effects, which accommodate cross-country differences in definitions of private R&D and differential R&D spill-in effects from EU countries not included in our sample. They also represent time-invariant but unspecified country-specific other factors, for example, agro-climatic conditions, major soil types, and proximity to other specific countries. We assume a constant relationship among the set of variables in our model and also that problems sometimes ascribable to random deviation of the characteristics of countries from their mean values are not important. 39 Besides, the econometric model is to be fitted to data over a relatively short time period, and randomeffect estimates tend to be quite imprecise under these conditions.
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The Results Equation (1) for each of the nine countries is stacked as a seemingly unrelated regression model, with coefficients on identical regressors being constrained to be the same across countries, except for the intercept, and fitted by the Zellner seemingly unrelated regression (SUR) estimation method with crosscountry heteroscedasticity. 41 Thus, there are 90 observations obtained by pooling the 10 observations per country over the nine EU countries. The estimated coefficients of the aggregate private agricultural R&D investment equation and associated t-ratios are presented in table 4. 42 Overall, the fitted model performs well. All coefficients are different from zero at the 5% significance level, and the hypothesis that the R&D investment equation has no explanatory power (i.e., all coefficients except for country fixed effects are zero) is rejected at the 1% significance level. Regression equation (1), table 4 , has a large (0.97), indicating that a very 2 R large share-over 97%-of the variation of the log private agricultural R&D investments about its mean is explained by the regressors in the model.
Turning to particular effects, a higher real interest rate decreases private Note.-EU p European Union. * Each country has its own separate intercept, which is the coefficient of the countryspecific dummy variable, i.e., there is no common intercept term.
R&D investment. The real opportunity cost of capital matters for private agricultural R&D investment. Public and private R&D capital are complementary in affecting private R&D investment, that is, the estimated value of is positive, and the main effect of private R&D capital is also positive, b 13 so that the effect of private R&D capital on private R&D investment is strictly positive. The impact elasticity, evaluated at the sample mean of public agricultural research capital, is 0.985. Thus, having done more private R&D in the past allows a country to make better use of the past public R&D.
Additional public R&D capital has a negative direct and positive indirect effect on private R&D investment. At low levels of private R&D capital, for example, at or below the sample mean, the direct effect dominates, and additional public R&D capital substitutes for private R&D investment. Public R&D, however, turns into a complement provided that there is enough private R&D capital for firms to benefit, which occurs when private R&D capital is 1.25 times its sample mean value. Hence, additional public R&D capital sometimes decreases and at other times increases private R&D investment. 43 The implication is that a reduction in public R&D capital has a positive effect on aggregate private R&D investment, and it may be large enough to compensate for the loss of public expenditures. Hence, total (public and private) aggregated agricultural R&D investment may increase, and the private R&D share may rise dramatically.
We have striking results that transnational private R&D transfers appear to crowd-out privately funded R&D in the particular country that receives the transfers. First, transnational privately funded R&D is "closer" to the private R&D of a country than public R&D and should be a substitute. Second, spillovers proxy for product market rivalry between firms in different countries. Hence, private R&D does not have the same transnational effects that public R&D does.
The impact of additional agricultural output on private agricultural R&D investment is positive, and the impact elasticity is 1.20. Larger agricultural output leads to larger private R&D investment, but it is surprising that the impact elasticity is larger than one. The estimated coefficient for crop share of agricultural output is negative. Hence, output composition matters for private R&D investment decisions, and livestock production has more favorable effects on private R&D investments than does crop production.
Our results show that the quality of a country's institutions is an important factor in private agricultural R&D investment decisions. Consistent with expectations, when a country has stronger patent rights, private agricultural R&D investment increases significantly. For efficient bureaucracy and contract enforcement, the estimates of and are both negative, but the coefficient b b 10 11 of the interaction term is positive. When evaluated at the sample mean, (b ) 14 the marginal effect of efficient bureaucracy and contract enforcement on private agricultural R&D investment is positive, 0.16 and 1.29, respectively-fewer bureaucratic delays and better contract enforcement provide a good politicaleconomic climate for private agricultural R&D investment. The positive sign for suggests that the contract enforcement and efficient bureaucracy are types b 14 of complements for affecting aggregate private R&D investment.
The effect of openness is negative. This result suggests a local politicaleconomic climate that is favorable to domestic firms relative to foreign firms is most advantageous to local private agricultural R&D investment. Hence, it is consistent with agricultural technologies needing to be adapted to local economic conditions. Finally, the estimates of the country-specific fixed effects differ by a large magnitude, but we place little emphasis on the size of these parameters.
Although the empirical results for the institutional variables are quite strong, a joint test of the null hypothesis of "no effect of institutions"-that is, that in equation (1) sample value of the chi-squared statistic for the Wald test is 238, which is larger than the critical value (of 11.1) with 5 degrees of freedom at the 5% significance level. 44 Furthermore, when these restrictions are imposed on the institutional variables (table 4, as regression eq. [2] ), the size (and statistical significance) of the estimated coefficients for some of the remaining variables changes significantly. Hence, institutional variables do significantly affect domestic private agricultural R&D investments.
Conclusions
Research and development have been shown to be major forces behind the growth in agricultural output, especially agricultural productivity increases. Some studies have focused on modeling and explaining the public sector's willingness to invest in agricultural research in an environment where R&D produces impure public goods and positive interjurisdictional spill-ins are regional rather than widespread. 45 The current study, however, is one of the first to examine aggregate private agricultural R&D investment using a panel of developed countries and to identify separate effects of economic incentives, institutions, and public policies. Furthermore, it is the first study to provide estimates of the impacts of public agricultural research capital on domestic private agricultural R&D investment. The impact is in fact negative at and below the sample mean; that is, partial crowding-out occurs. Hence, if public agricultural R&D investments decreases, private agricultural research will increase by enough to offset the decline in public R&D investment. One possibility is that over the time period of the study, the EU countries have invested too heavily in applied research that is competitive with the private sector and not enough in basic-general and pretechnology sciences. Consistent with our findings, starting in the 1990s the national governments in some EU countries transferred or sold part of their agricultural research units to the private sector; for example, in both the United Kingdom and the Netherlands, the ministries of agriculture converted their agricultural research units into quasi-private institutions. Overall, public and private agricultural research in these nine EU countries has been complementary, holding trend factors constant. The study also finds a small negative transnational externality associated with private agricultural R&D investment in other EU countries, suggesting that private R&D discoveries are transmitted across country boundaries in a way that is competitive with or crowds-out local private R&D investments. Over time, this tendency is expected to grow as the EU becomes a single market.
Private sector R&D investment is shown to respond positively to the size of a country's agriculture, and the response elasticity is larger than one. Private agricultural R&D investments in the EU are negatively related to the relative importance of crop output in total agricultural production, other things equal. However, in the United States, the impression is that private R&D is more closely tied to crop than livestock production. 46 The hypothesis that institutions do not matter was rejected. Stronger patent rights, better contract enforcement, efficient civil bureaucracy, and protectionism of local firms were shown to increase aggregate private agricultural R&D investment unconditionally, other things equal. Furthermore, better contract enforcement and efficient civil bureaucracy appear to be complementary, which can be a large advantage for private R&D investments in some countries.
Over the period 1960-95, intellectual property rights in Western European countries have been strengthened. Given our results, this seems to have been one force for large private sector agricultural R&D investment. However, the finding of public agricultural R&D capital partially crowding-out private agricultural R&D investment suggests that national governments in the EU may not have adjusted fully to these changes. Restructuring public agricultural research so that it is complementary with private agricultural R&D investment would seem to be a good public policy for the future.
Appendix
Some particular measurement problems in the R&D data by country are outlined.
Austria. Expenditure data are based on the OECD statistical series: "Public Finding of R&D by Socio-Economic Objective: Agriculture, Forestry and FisheriesVersion 2." According to Phil Pardey and J. Roseboom, a complete breakdown of the advancement of knowledge item (including university funds) would certainly result in some increase in the agricultural research expenditure estimates. 47 France. The National Centre for Scientific Research is included in the higher education sector, whereas in other countries such as Italy, this type of organization is classified in the government sector. Business enterprise R&D expenditure data by industry and by source of funds are only available for intra-plus extramural expenditure. This is the reason why the total by source of funds by industry is higher than the business enterprise R&D by industry.
Germany. OECD data for government R&D appropriations in Germany cover Western Germany only until 1990 and unified Germany after 1990. Through 1985, the technology balance of payments data for Germany cover transactions concerning patents, licenses, trademarks, models, and designs. After 1985, these data also cover technical services and industrial R&D. There are breaks between 1990 and 1991 as well as between 1991 and 1992 in total and socioeconomic objectives data.
Italy. Through 1990, the data represent the sum of intramural and extramural R&D expenditures, but after 1990, only the intramural R&D expenditure are included. The pre-1991 data for Italy are thus only partially comparable with those of other countries.
Netherlands. Netherlands has reorganized research in the Ministry of Agriculture and created a Knowledge Center associated with Wageningening Agricultural University. This shifts some R&D expenditures from the public to the university.
Portugal. Expenditure indicators are based on a classification of scientific disciplines rather than of the socioeconomic objective. According to Pardey and Roseboom, consistency in institutional coverage between observations is difficult to verify, especially for the earlier years.
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Spain. Data are underestimated between 10% and 15% per year because R&D personnel data for higher education only include researchers but not other staff. In October 1986, Spain joined the European patent convention. As a result, the number of patent applications for 1986 is not comparable with later series.
Sweden. Data for R&D performed by the government and private nonprofit institutions are underestimated because social sciences and humanities are excluded. The methodology for measuring government R&D appropriations has been subject to annual changes since 1991, so that a comparison of the data from 1990 to 1994 would appear to be of limited value only.
United Kingdom. Between 1985 and 1986 some government agencies were reclassified to the business enterprise sector. This caused a break in series for the data covering the performance and financing of government expenditure in R&D.
